DIRS.INFO The most relevant business & tech news

☆ Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
▼ + stars: | 2024-02-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Senators will question the CEOs of Johnson & Johnson , Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. Prescription drug prices in the U.S. are also more than 2.5 times as high as those in other high-income nations, another federal report showed. The Senate Health, Education, Labor and Pensions Committee says that's especially true for some of the top drugs from J&J, Merck and Bristol Myers Squibb. ET and include testimony from J&J CEO Joaquin Duato, Merck CEO Robert Davis and Bristol Myers Squibb CEO Chris Boerner. A spokesperson for Bristol Myers Squibb did not immediately respond to a request for comment ahead of the hearing.

Persons: Sen, Bernie Sanders, Ed Markey, Joaquin Duato, Robert Davis, Chris Boerner, Duato, Davis, Bristol Myers, Eli Lilly's, J Organizations: Capitol, Johnson, Merck, Bristol Myers Squibb, U.S, Health, Education, Labor, Pensions, Bristol Myers, CNBC, J, Bristol Locations: U.S

☆ Under Bernie Sanders’s Glare, Pharmaceutical Chiefs Will Testify on Drug Prices
▼ + stars: | 2024-02-08 | by ( Noah Weiland | Rebecca Robbins | ) www.nytimes.com time to read: +1 min

The chief executives of three major pharmaceutical companies are set to appear in front of the Senate health committee on Thursday to defend how much they charge for drugs in the United States, drawing them further into a confrontation with lawmakers and the Biden administration over the cost of some of the most widely used prescription medications. The three executives scheduled to testify — Joaquin Duato of Johnson & Johnson, Robert M. Davis of Merck and Christopher Boerner of Bristol Myers Squibb — are expected to clash with the health committee’s chairman, Senator Bernie Sanders of Vermont, an independent who has made reining in drug prices a signature cause of his late-career years in Congress. Mr. Sanders plans to focus the hearing on why drug prices are higher in the United States than in other wealthy countries. His staff has singled out several widely used drugs, including Eliquis, a blood thinner made by Bristol Myers Squibb, and Januvia, a diabetes drug from Merck, that can be bought for much less in Canada and Europe than in the United States.

Persons: Biden, — Joaquin Duato, Johnson, Robert M, Davis, Christopher Boerner, Bernie Sanders of, Sanders Organizations: Merck, Bristol Myers Squibb Locations: United States, Bernie Sanders of Vermont, Canada, Europe

Three names in the industry – Johnson & Johnson , Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. They join Bristol Myers Squibb CEO Chris Boerner, who agreed to the panel's initial invitation to appear. But why is the committee targeting Merck, J&J and Bristol Myers Squibb in the first place? J&J, Merck and Bristol Myers Squib are all suing to halt the talks, which will establish new prices that will go into effect in 2026. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer.

Persons: Annika Kim Constantino, – Johnson, Sen, Bernie Sanders, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Eli Lilly's, Januvia, Bristol Myers, He's, Biden, Merck's, Myers, Eliquis, Mike Perrone, it's Organizations: CNBC.com, Johnson, Merck, Bristol Myers Squibb, Bristol Myers, Medicare, Bristol, CNBC, pharma Locations: U.S, drugmakers

☆ Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
▼ + stars: | 2024-01-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Sen. Bernie Sanders, I-Vt., holds his news conference with Sen. Ed Markey, D-Mass., in the Capitol on Thursday, January 25, 2024, on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices. The CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders announced Friday, as lawmakers ramp up efforts to rein in health-care costs for Americans. Meanwhile, Bristol Myers Squibb CEO Chris Boerner and another unnamed pharmaceutical CEO agreed to initial invitations to testify. The push to cut drug prices is one of the rare issues that has united both major political parties in recent years — though they have often backed different approaches to doing so. Last year, the Senate Health Committee similarly heard testimony from the CEOs of Moderna , Eli Lilly , Novo Nordisk and Sanofi on high drug prices.

Persons: Sen, Bernie Sanders, Ed Markey, Johnson, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Januvia, Bristol Myers, Joe Biden's, J, Eli Lilly Organizations: Merck, Johnson, Health, Education, Labor, Pensions, Bristol Myers, Bristol, J, Moderna, Novo Nordisk, Sanofi Locations: U.S

☆ Watch CNBC's full interview with Johnson & Johnson CEO Joaquin Duato
▼ + stars: | 2023-12-05 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Johnson & Johnson CEO Joaquin DuatoJohnson & Johnson chairman and CEO Joaquin Duato, joins 'Squawk Box' to discuss the company's long-term competitive growth plan, 2024 guidance, the implementation and impact of A.I. and machine learning, product pipeline outlook, and more.

Persons: Johnson, Joaquin Duato Johnson, Joaquin Duato Organizations: Johnson

☆ J&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlook
▼ + stars: | 2023-12-05 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJ&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlookJohnson & Johnson chairman and CEO Joaquin Duato, joins 'Squawk Box' to discuss the company's long-term competitive growth plan, 2024 guidance, the implementation and impact of A.I. and machine learning, product pipeline outlook, and more.

Persons: Joaquin Duato, Johnson

☆ Aid agency urges Johnson & Johnson to improve access to tuberculosis drug
▼ + stars: | 2023-09-30 | by ( ) www.reuters.com time to read: +2 min

FILE PHOTO:The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. REUTERS/Yves Herman/File Photo Acquire Licensing RightsGENEVA, Sept 29 (Reuters) - Global health aid agency Unitaid has written to Johnson & Johnson's (JNJ.N) CEO, Joaquin Duato, urging "immediate action" to expand access to the company's tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives. The agency is urging J&J to remove all secondary patents and ensure that lower prices are available to all countries with high TB cases. TB, a bacterial disease that mostly affects the lungs, is preventable and treatable, but 10 million people catch it annually. Around 1.6 million people died from TB in 2021, almost entirely in low- and middle-income countries, according to the World Health Organization (WHO).

Persons: Johnson, Yves Herman, Unitaid, Joaquin Duato, Philippe Duneton, J, Emma Farge, Jennifer Rigby, Devika Nair, Susan Fenton, Elaine Hardcastle, Leslie Adler Organizations: Johnson, REUTERS, Rights, UN, Assembly, World Health Organization, WHO, Thomson Locations: Brussels, Diegem, Belgium, South Africa, Belarus, Ukraine

☆ Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
▼ + stars: | 2023-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer. J&J owns 89.6% of Kenvue's common stock, which amounts to more than 1.72 billion shares. The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue's common stock at a 7% discount. J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. When asked about J&J's planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC's "Squawk on the Street" that the company is "pleased with the way that the IPO has been received by shareholders."

Persons: Johnson, J, Joaquin Duato, Duato, Kenvue, J's, Thibaut Mongon, CNBC's Organizations: J Locations: Kenvue

☆ 3 health-care stocks are in the headlines. How the news impacts our investments
▼ + stars: | 2023-07-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

In April, alongside its first-quarter results, J & J raised its full-year sales guidance by about $1 billion and its earnings-per-share outlook by 15 cents. Clearing this overhang would help reduce the discount at which J & J shares to pharmaceutical peers, the firm said. The Club's take: JPMorgan's thinking on J & J aligns quite closely with our own. The dark cloud of talc lawsuits continues to keep a lid on J & J's stock price. Joaquin Duato, chief executive officer of Johnson & Johnson, at the company's headquarters in New Brunswick, New Jersey, U.S., on Thursday, April 21, 2022.

Persons: Johnson, Eli Lilly, J, Wells, Wells Fargo, Eli Lilly's, —, Eisai, Biogen, Bloomberg, we've, Jim Cramer's, Jim Cramer, Jim, Joaquin Duato, Amir Hamia Organizations: Johnson, JPMorgan, pharma, U.S ., Humana, UnitedHealth, Bloomberg, U.S, Mayo Clinic, Club, GE Healthcare, CNBC, Getty, & $ Locations: U.S, California, Wells Fargo, Rochester , Minnesota, New Brunswick , New Jersey

☆ Rupert Murdoch Can Do Whatever He Wants. It’s Becoming a Problem. - The New York Times
▼ + stars: | 2023-07-04 | by ( William D. Cohan | ) www.nytimes.com time to read: +3 min

Mr. Murdoch’s heir apparent, Lachlan, defended Fox and the Dominion settlement when speaking to investors on May 9. Contrast Mr. Murdoch with, say, Jamie Dimon, the chairman and chief executive of JPMorgan Chase, the nation’s largest bank. Does anyone at Fox or News Corp hold Mr. Murdoch accountable in the same way? One way to rein in Mr. Murdoch may lie with Smartmatic. Smartmatic, or even the recently filed shareholder lawsuit against Fox, could end up pressuring Fox, and indirectly News Corp, to scrap their dual-class stock structures.

Persons: Murdoch’s, Lachlan, ”, “, ” Ms, Minow, Roberts, Shari Redstone, Murdoch, Jamie Dimon, JPMorgan Chase, Joaquin Duato, Johnson, Dimon, he’s, Duato Organizations: Fox, Fox News, Fox Corporation, Comcast, Paramount Global, JPMorgan, Mr, News Corp Locations: America

☆ Johnson & Johnson's consumer health unit Kenvue started trading. What it means for J&J shareholders like us
▼ + stars: | 2023-05-05 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

For now, it's not exactly clear how J & J will go about the second step of this divestiture. In this scenario, we would have the option to relinquish some, all or none of our J & J shares. In fact, our optimism around the breakup was a big reason we bought into J & J nearly a year ago . J & J continues to argue against claims that its baby powder and other talc products caused cancer lack merit. "Look at it as a whole company today, knowing that [roughly] 10% doesn't belong to J & J," explained Cantor Fitzgerald analyst Louise Chen, who has a buy rating and maintains a $215 price target on J & J.

☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
▼ + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.

FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo(Reuters) - Johnson & Johnson will look for opportunities to merge with or acquire firms that add value to its focus areas of eye care, surgical robots, orthopedics and cardiovascular products, the company’s Chief Executive Officer Joaquin Duato said on Monday. The healthcare giant is in the process of spinning off its consumer healthcare business under the brand Kenvue to focus on its pharmaceutical and medical devices businesses. J&J last month completed its acquisition of heart pump maker Abiomed for $16.6 billion, which will operate as an independent division in its medical devices business. The company’s CEO expects J&J to continue growing towards its goal of $60 billion in pharmaceutical sales by 2025, and is confident of exceeding current Street expectations by the targeted year.

☆ What to watch for as J&J gets ready to split into two separate companies next year
▼ + stars: | 2022-12-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +11 min

During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." According to projections from J & J and rival Medtronic (MDT), the robotics market captures a low 2% to 3% of global procedures. In an economic slowdown, J & J is a solid name to own that can outperform the broader market. We also like that J & J has consistently raised its dividend. We rate J & J a 1 for the Club , meaning we would buy the stock at current levels given it aligns with our strategy.

Organizations: & $

[1/2] The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. J&J is focused on its pharmaceuticals and medical devices operations with the consumer health spinoff expected by November 2023. Chief Executive Joaquin Duato has said he will look to build up the medical devices unit through acquisition. Abiomed will operate as a standalone business within the healthcare conglomerate's medical technology division. J&J's medical technology business includes surgical, orthopedic and various other devices.

☆ Regulatory approvals for AbbVie, J&J bolster the Club investment case
▼ + stars: | 2022-10-20 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

The technology platform — called Teligen — was developed by DePuy Synthes, a J & J subsidiary under the medical technology umbrella. J & J said Thursday it expects Teligen to be available in the U.S. later this year. J & J CEO Joaquin Duato, who took over the role earlier this year, has spoken about the complementary nature of the med tech and pharmaceutical divisions. That's where Johnson & Johnson is going to play, in that intersection. We like owning J & J for its defensive characteristics right now, while all three divisions are under the same roof.

☆ Watch Jim Cramer's full interview with Johnson & Johnson CEO Joaquin Duato
▼ + stars: | 2022-09-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch Jim Cramer's full interview with Johnson & Johnson CEO Joaquin DuatoThe "Mad Money" host interviewed Johnson & Johnson CEO Joaquin Duato on Tuesday's episode of the show.

☆ Johnson & Johnson CEO touts 'smart' data approach to medicine breakthroughs at new research center
▼ + stars: | 2022-09-20 | by ( Paulina Likos | ) www.cnbc.com time to read: +1 min

Johnson & Johnson is honing in on finding new solutions to advance health care treatments, CEO Joaquin Duato told CNBC's Jim Cramer on Tuesday. Duato, who became CEO in January, said this is an exciting moment for the company because it's on the path of facilitating the future of medicine. Johnson & Johnson is the largest pharmaceutical company in the world. Its pharma business sales jumped 12.4% to $13.3 billion in the second quarter, while medtech and consumer health sales grew 3.4% to $6.8 billion and 2.9% to $3.8 billion, respectively. Disclaimer: Cramer's Charitable Trust owns shares of Johnson & Johnson.

☆ Johnson & Johnson CEO touts 'smart' data approach to new medicines at new research center
▼ + stars: | 2022-09-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJohnson & Johnson CEO touts 'smart' data approach to new medicines at new research centerCNBC's Jim Cramer spoke with Johnson & Johnson CEO Joaquin Duato on Tuesday's episode of "Mad Money."

Search resuls for: "Duato"

19 mentions found